The Committee for Medicinal Products for Human Use (CHMP) decided that INTEGRILIN’ s benefits are greater than its risks to prevent early myocardial infarction.
Inimtervishoius kasutatavate ravimite komitee otsustas, et INTEGRILINi kasulikkus varase müokardi infarkti ennetamisel ületab selle riske.